SCHEMBL23577333

SCHEMBL23577333

CN(c1ncc(Br)s1)c1nc(Cl)nc2cc(Cl)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.35
PDGFRB P09619 1/20 0.35
KDR P35968 1/20 0.35
POLB P06746 1/20 0.35
CHKA P35790 1/20 0.34
NR4A2 P43354 1/20 0.33
GBA1 P04062 1/20 0.32
MPO P05164 1/20 0.32
CSF1R P07333 1/20 0.32
KMT2A Q03164 1/20 0.31
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
TUBB4A P04350 1/20 0.30
TUBB P07437 1/20 0.30
TUBA3C P0DPH7 1/20 0.30
TUBA1B P68363 1/20 0.30
TUBA4A P68366 1/20 0.30
TUBB4B P68371 1/20 0.30
TUBB3 Q13509 1/20 0.30
TUBB2A Q13885 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30014065 1.00 EGFR (0.35) EGFRPDGFRBKDRPOLBCHKA
SCHEMBL23577932 0.85 GAA (0.36) POLBCHKANR4A2MPOKMT2A
SCHEMBL29909528 0.85 GAA (0.36) POLBCHKANR4A2MPOKMT2A
SCHEMBL29909194 0.74 MAT2A (0.35) SMN1; SMN2
SCHEMBL23576994 0.74 MAT2A (0.35) SMN1; SMN2
SCHEMBL24808397 0.74 EGFR (0.36) EGFRPDGFRBKDRPOLBCHKA
SCHEMBL30014123 0.72 EGFR (0.39) EGFRPDGFRBKDRPOLBCHKA
SCHEMBL23577329 0.72 EGFR (0.44) EGFRPDGFRBKDRCHKACSF1R
SCHEMBL23577130 0.72 EGFR (0.39) EGFRPDGFRBKDRPOLBCHKA
SCHEMBL29909602 0.72 EGFR (0.44) EGFRPDGFRBKDRCHKACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 CN disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 US disclosed
CN-117736207-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-03-22 CN disclosed
CN-115362003-B Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-03-22 CN disclosed
US-11845723-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2023-12-19 US disclosed
CN-115362003-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2022-11-18 CN disclosed
EP-4081305-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2022-11-02 EP disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK EGFR 1239/4885PDGFRB 1157/4885KDR 1993/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK EGFR 1239/4885PDGFRB 1157/4885KDR 1993/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK EGFR 1239/4885PDGFRB 1157/4885KDR 1993/4885
US-11845723-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK EGFR 1239/4885PDGFRB 1157/4885KDR 1993/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK EGFR 1239/4885PDGFRB 1157/4885KDR 1993/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK EGFR 1239/4885PDGFRB 1157/4885KDR 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.